Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

Exclusion Criteria

• •Have a defined need for adenosine diphosphate (ADP)-receptor inhibitor therapy, such as any of the following (or any other condition that in the Investigator's judgment would require such therapy):
• •Within =\< 12 months of an acute coronary syndrome (ACS) event (unstable angina \[UA\], non-ST-elevation myocardial infarction \[NSTEMI\], or ST-elevation myocardial infarction \[STEMI\]) regardless of initial treatment (that is, invasive versus noninvasive)
• •Subjects who underwent angioplasty within 12 months including bare-metal stent and/or a drug-eluting stent
• •Had any stent placed in an unprotected left main coronary artery or in the last patent artery within the last 12 months
• •Received thienopyridine therapy within 30 days of study entry
• •Plan to undergo coronary revascularization at any time during the trial
• •Presence or history of any of the following: ischemic or hemorrhagic stroke; transient ischemic attack (TIA); intracranial neoplasm; arteriovenous malformation, or aneurysm; intracranial hemorrhage; head trauma (within 3 months of study entry)
• •History of refractory ventricular arrhythmias with an increased risk of bradycardic events (eg, subjects without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree atrioventricular (AV) block or bradycardic-related syncope)
• •History or evidence of congestive heart failure (New York Heart Association Class III or above =\< 6 months before screening
• •Severe hepatic impairment
• •History of uric acid nephropathy
• •Uncontrolled hypertension, or systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg at screening
• •Severely impaired renal function (glomerular filtration rate \< 30 mL/minute) or on dialysis
• •At risk for bleeding
• •Taking prohibited medications